PTX


Cantor Slashes Price Target for Pernix Therapeutics Holdings Inc on Back of Commercial Execution Concerns

Cantor’s healthcare analyst Irina Rivkind Koffler weighed in with a cautious stance on shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX), reducing the price target to $8.50 (from $11.

Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014

2014 was an eventful year on Wall Street with many ups and downs. Although many analyst recommendations made in 2014 were profitable, many …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts